Keeping Track: Targeted Oncologics Take Center Stage, Led By Retevmo And Tabrecta Approvals

The latest oncology news and highlights from the Pink Sheet’s FDA Performance Tracker.

Keeping Track Feature image

Novel oncology approvals by the US Food and Drug Administration continue to come in fast and furious. With the approvals of Eli Lilly & Co.’s Retevmo and Novartis AG’s Tabrecta last week, the agency has cleared nine new molecular entities or novel biologics for cancer treatment in 2020 to date, making up half of the year’s novel approvals.

Even more striking is the speed of the oncology reviews. Only one of the nine novel agents was approved on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers